Viljoen, Adie

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1,419

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial

Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 790

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Lingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 298

Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study

Meek, C., Wierzbicki, A. S., Jewkes, C., Twomey, P. J., Crook, M. A., Jones, A., & Viljoen, A. (2012) · Current Medical Research and Opinion

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 52

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.

Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 45

Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK

Viljoen, A., Hoxer, C. S., Johansen, P., Malkin, S., Hunt, B., & Bain, S. C. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 45

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 11

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3

Viljoen, A., Pantalone, K. M., Galindo, R. J., Cui, X., Huh, R., Hemmingway, A., Fernández Landó, L., & Patel, H. (2023) · Diabetes Therapy

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 11

Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice

Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 10

Lipid clinic experience with bempedoic acid in three UK centres

Jakubowska, A., Al Hasani, W., Williams, J., MacMahon, Z., Balbas, B., Crook, M. A., Viljoen, A., Reynolds, T. M., & Wierzbicki, A. S. (2024) · Current Medical Research and Opinion

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 5